Summary
There is a troubling lack of effective pain treatments after major surgery. Especially after musculoskeletal procedures, patients experience debilitating pain now treated with opioids. Opioids provide insufficient pain relief, have many toxic side-effects, and are highly addictive. Pain and opioid-related side-effects impede early mobilisation and recovery and are the primary reasons for extended hospital stays.
SentryX is developing revolutionary drug delivery technology to extend the effects of a well-established local pain blocker called bupivacaine. Its initial use case in spine fixation surgery, Bupi-Ring, delivers bupivacaine directly to the surgical site for more than 72 hours without changing the existing surgical workflow. Non-opioid local pain relief in this critical early phase of recovery will promote early mobilisation, shorten hospital stays, prevent complications, and save costs. This project will demonstrate Bupi-Ring’s safety and efficacy in humans for the first time.
SentryX is developing revolutionary drug delivery technology to extend the effects of a well-established local pain blocker called bupivacaine. Its initial use case in spine fixation surgery, Bupi-Ring, delivers bupivacaine directly to the surgical site for more than 72 hours without changing the existing surgical workflow. Non-opioid local pain relief in this critical early phase of recovery will promote early mobilisation, shorten hospital stays, prevent complications, and save costs. This project will demonstrate Bupi-Ring’s safety and efficacy in humans for the first time.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190122961 |
| Start date: | 01-04-2023 |
| End date: | 31-03-2026 |
| Total budget - Public funding: | 5 687 678,50 Euro - 2 500 000,00 Euro |
Cordis data
Original description
There is a troubling lack of effective pain treatments after major surgery. Especially after musculoskeletal procedures, patients experience debilitating pain now treated with opioids. Opioids provide insufficient pain relief, have many toxic side-effects, and are highly addictive. Pain and opioid-related side-effects impede early mobilisation and recovery and are the primary reasons for extended hospital stays.SentryX is developing revolutionary drug delivery technology to extend the effects of a well-established local pain blocker called bupivacaine. Its initial use case in spine fixation surgery, Bupi-Ring, delivers bupivacaine directly to the surgical site for more than 72 hours without changing the existing surgical workflow. Non-opioid local pain relief in this critical early phase of recovery will promote early mobilisation, shorten hospital stays, prevent complications, and save costs. This project will demonstrate Bupi-Rings safety and efficacy in humans for the first time.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Geographical location(s)